Tag Archive for: Anti-Microbial Resistance

Novo Holdings advances antimicrobial resistance strategy with acquisition of Paratek Pharmaceuticals

/in

Paratek’s successful commercialisation platform to advance novel therapies developed organically and through acquisitions Paratek adds ‘final-mile’ capabilities to AMR efforts COPENHAGEN, September 21, 2023 – With the closing of the acquisition of Paratek Pharmaceuticals, Inc. (“Paratek”), a commercial-stage biopharmaceutical company focused on the development and commercialisation of novel therapies for life-threatening diseases and other public health […]

Read more

Novo Holdings participates in EUR 30 million Series A financing of Bactolife, a Danish biotech company dedicated to strengthening the gut microbiome and fighting antimicrobial resistance

/in

Novo Holdings today announced it has participated in the EUR 30 million Series A Financing of Bactolife. ATHOS led the round, with participation from the Bill & Melinda Gates Foundation, Novo Holdings and other existing investors. Bactolife is a Danish bioindustrial company developing proprietary Binding Proteins™, which strengthen the gut microbiome of humans and animals […]

Read more

Destiny Pharma’s Call to Arms to Combat AMR

/in

CEO Neil Clark and CSO Dr Bill Love from Europe’s leading anti-infectives biotech company Destiny Pharma, on how the makers and influencers of health policy could fuel a renaissance in drug development…

Read more